ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
Dow Jones
39,118.86
-0.12%
US Dollar vs MXN
18.3328
-0.57%
Brent Oil
84.85
-0.66%
Bitcoin
60,165.12
-2.35%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Apollomics Inc (APLMW)

  7. Apollomics Inc (APLMW) Noticias

APLMW

Apollomics (APLMW)

Apollomics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:APLMW
FechaHoraFuenteTítuloSímboloCompañía
04/06/202407:00GlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMWApollomics Inc
30/05/202415:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLMWApollomics Inc
29/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APLMWApollomics Inc
29/05/202416:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:APLMWApollomics Inc
29/05/202407:00GlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMWApollomics Inc
24/05/202416:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
24/05/202415:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLMWApollomics Inc
20/05/202415:32Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:APLMWApollomics Inc
20/05/202415:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
08/05/202415:05GlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMWApollomics Inc
25/04/202407:30GlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMWApollomics Inc
10/04/202406:00GlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
02/04/202407:00GlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
28/03/202406:00GlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMWApollomics Inc
26/03/202407:00GlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMWApollomics Inc
04/03/202406:00GlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMWApollomics Inc
07/02/202406:00GlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMWApollomics Inc
19/01/202415:15GlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMWApollomics Inc
17/01/202415:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMWApollomics Inc
03/01/202406:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMWApollomics Inc
02/01/202415:30GlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMWApollomics Inc
04/12/202306:00GlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMWApollomics Inc
29/11/202306:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMWApollomics Inc
28/11/202306:00GlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMWApollomics Inc
16/11/202307:30GlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMWApollomics Inc
31/10/202307:30GlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMWApollomics Inc
26/10/202307:50GlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMWApollomics Inc
23/10/202307:30GlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMWApollomics Inc
16/10/202317:55GlobeNewswire Inc.Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023NASDAQ:APLMWApollomics Inc
28/09/202315:17GlobeNewswire Inc.Apollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateNASDAQ:APLMWApollomics Inc
 Showing the most relevant articles for your search:NASDAQ:APLMW

Su Consulta Reciente

NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
COIN
ETHUSD
Ethereum
SPI
SP500
S&P 500
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
USOTC
BASFY
BASF (QX)
NYSE
MCD
McDonalds
NYSE
CVX
Chevron
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados